Rapid determination of alanine aminotransferase (ALT) enables fast, quantitative assessment of hepatocellular injury from serum, plasma, or whole blood, with results available in minutes rather than hours. Because ALT is the most liver-specific enzyme in routine clinical chemistry, rapid ALT testing is widely used for hepatitis screening, blood donor qualification, drug-induced liver injury monitoring, and point-of-care liver function evaluation. This article explains the technical principles, sample requirements, assay formats, performance characteristics, and practical applications of rapid ALT measurement.
Technical Overview
Alanine aminotransferase (ALT, EC 2.6.1.2), formerly known as serum glutamic pyruvic transaminase (SGPT), is a pyridoxal phosphate-dependent enzyme that catalyzes the reversible transfer of an amino group from L-alanine to 2-oxoglutarate (alpha-ketoglutarate), producing pyruvate and L-glutamate. Although ALT is present in the liver, kidney, heart, and skeletal muscle, its highest concentration occurs in hepatocyte cytoplasm, which makes serum ALT activity the most sensitive and specific routine marker of hepatocellular damage.
When hepatocyte membrane integrity is compromised by viral hepatitis, ischemia, toxins, drugs, autoimmune attack, or fatty liver disease, ALT is released into the circulation and its serum activity rises, often before clinical symptoms appear. Quantitative ALT measurement therefore serves as a first-line test in liver disease screening, diagnosis, and longitudinal monitoring.
Rapid ALT determination refers to assay systems specifically engineered for short turnaround time: pre-packaged liquid or dry reagents, cartridge-based or strip-based chemistry, portable or benchtop analyzers, and simplified workflows that eliminate manual reagent preparation. Modern rapid systems can report a quantitative result from as little as 10-20 microliters of sample within 5-15 minutes, with analytical performance traceable to the IFCC (International Federation of Clinical Chemistry and Laboratory Medicine) reference measurement procedure. Typical specifications include:
- Measuring range of approximately 3-500 U/L without dilution, extendable by automated dilution of high-activity samples.
- Imprecision of within-run CV less than 5% and between-run CV less than 10% at clinically relevant activities.
- Result reporting in U/L (1 U/L = 16.67 nkat/L) with sex- and age-specific reference intervals.
- Sample-to-answer operation with barcode identification, onboard calibration, and automated quality control checks.
Testing Samples
Serum
Serum is the conventional sample for ALT determination. Venous blood is collected into a plain tube or a gel separator tube, allowed to clot for 20-30 minutes, and centrifuged to obtain clear serum. Serum is compatible with all rapid ALT platforms and is the recommended matrix when the sample can be processed centrally.
Plasma
Lithium heparin or EDTA plasma is acceptable on most analyzers and shortens turnaround time by eliminating the clotting step. Anticoagulants such as citrate or fluoride are generally not recommended because of dilution effects or enzyme inhibition; the reagent or analyzer instructions for use must always be checked for validated matrices.
Whole Blood
Capillary (fingerstick) or venous whole blood is used on point-of-care and dry-chemistry systems. These devices separate plasma from cells on a multilayer slide or within a microfluidic cartridge, so no centrifuge is required. Whole blood testing is particularly valuable in field screening, blood banks, emergency settings, and resource-limited laboratories.
Sample Handling and Stability
- ALT is stable in serum or plasma for at least 24 hours at 20-25 degrees C, for 3-7 days at 2-8 degrees C, and for several months at minus 20 degrees C or below.
- Repeated freeze-thaw cycles progressively inactivate ALT and must be avoided.
- Grossly hemolyzed, icteric, or lipemic samples can cause spectral interference, particularly in 340 nm kinetic assays; hemolysis should be minimized during phlebotomy and documented.
- Samples should be tightly capped and protected from evaporation and heat during transport.
Testing Items
The primary measurand is the catalytic activity concentration of ALT in serum, plasma, or whole blood, expressed in U/L or microkat/L. Depending on the platform and clinical purpose, rapid ALT testing may be delivered in the following formats:
- Quantitative ALT activity measurement with a numeric result and reference interval.
- Reflex or panel testing that adds AST and calculates the AST/ALT (De Ritis) ratio for differential diagnosis.
- Semi-quantitative or threshold-based screening formats, such as normal versus elevated at a defined cutoff, used in blood donor and community screening programs.
- Serial monitoring of the same patient for trend analysis during therapy.
Testing Methods
IFCC Kinetic Ultraviolet (Rate) Method
The internationally recommended method couples the ALT reaction with lactate dehydrogenase (LDH). In the first step, L-alanine and 2-oxoglutarate are converted to pyruvate and L-glutamate by ALT; in the indicator step, LDH reduces pyruvate to lactate while oxidizing NADH to NAD+. The rate of NADH disappearance, monitored as a decrease in absorbance at 340 nm (or at 334 nm and 365 nm with alternative extinction coefficients), is directly proportional to ALT activity. Two-reagent formats include a pre-incubation step that consumes endogenous pyruvate before the linear measurement window begins. Assays are standardized at 37 degrees C in Tris buffer at approximately pH 7.15 per the IFCC reference procedure, ensuring comparability across laboratories and instruments.
Pyridoxal-5'-Phosphate-Activated Assays
A small fraction of circulating ALT exists as the inactive apoenzyme. Some reagents add pyridoxal-5'-phosphate (P5P) to fully activate ALT, which can increase measured activity, particularly in patients with vitamin B6 deficiency. Because P5P activation affects standardization, IFCC recommends the non-P5P format for routine measurement, while P5P-supplemented reagents remain available for specific clinical or research purposes.
Colorimetric Endpoint Method (Reitman-Frankel / Dinitrophenylhydrazine)
In this classic approach, pyruvate generated by ALT reacts with 2,4-dinitrophenylhydrazine under alkaline conditions to form a red-brown hydrazone that is read at approximately 505-520 nm against a pyruvate standard curve. The method requires only a basic photometer and remains in use in low-resource settings, but it is more susceptible to interference from other keto acids and carbonyl compounds, has a narrower linear range, and has largely been superseded by the kinetic UV method.
Dry Chemistry and Point-of-Care Rapid Formats
Dry multilayer film slides and microfluidic cartridges integrate the ALT and indicator reactions in a stable, ready-to-use format. A drop of undiluted whole blood, serum, or plasma is applied to the cartridge; the device performs plasma separation, reagent reconstitution, incubation at controlled temperature, and reflectance or absorbance reading automatically. Quantitative results are typically displayed within 5-15 minutes. These systems feature barcoded calibration, electronic quality control lockout, and data transfer to laboratory or hospital information systems.
Workflow, Calibration, and Calculation
- Calibrate the analyzer with a calibrator traceable to the IFCC reference material and verify performance with two-level quality control materials.
- Apply the sample, initiate the reaction, and record the absorbance change per minute during the linear phase.
- Calculate activity using the molar absorptivity of NADH at 340 nm (6.22 L per mmol per cm), the optical path length, and the sample dilution factor; instrument software performs this computation automatically.
- Dilute and re-run samples above the upper limit of the measuring range, and flag results with hemolysis, icterus, or lipemia indices exceeding the specified thresholds.
Quality Control and Performance Characteristics
A robust rapid ALT program requires documented daily quality control at two activity levels, periodic calibration verification, and participation in external quality assessment or proficiency testing schemes. Key performance attributes to verify include:
- Accuracy, demonstrated by traceability to the IFCC reference measurement procedure and agreement with the central laboratory method within the declared bias.
- Precision, with within-laboratory CV typically below 5-10% across the measuring range.
- Linearity and reportable range, confirmed with dilution series of high-activity samples.
- Interference thresholds for hemoglobin, bilirubin, triglycerides, and ascorbic acid.
- Carryover below the manufacturer specification, particularly after high-activity samples.
Interpretation should always consider biological and pre-analytical factors: recent strenuous exercise, alcohol intake, body mass index, medications, and time of day can all shift ALT activity. Marked elevations above ten times the upper reference limit suggest acute hepatocellular injury and warrant urgent clinical evaluation, while persistent mild elevations most commonly reflect metabolic dysfunction-associated (fatty) liver disease.
Applications
- Clinical diagnostics: detection and monitoring of acute and chronic viral hepatitis, alcoholic and metabolic dysfunction-associated liver disease, cirrhosis, ischemic hepatopathy, and autoimmune hepatitis.
- Drug safety and therapeutic monitoring: scheduled ALT surveillance during antituberculosis therapy, statin or methotrexate treatment, chemotherapy, and use of herbal or dietary supplements; ALT is also a core safety parameter in clinical trials.
- Blood donor screening: rapid ALT measurement has historically served as a surrogate marker for non-A, non-B hepatitis and remains part of donor health assessment in some regions.
- Public health screening: community and workplace hepatitis B and C screening campaigns, vaccination program follow-up, and immigration or occupational health examinations.
- Point-of-care and resource-limited settings: emergency departments, intensive care units, dialysis units, mobile screening units, rural clinics, and field laboratories where a centrifuge and full chemistry analyzer are unavailable.
- Transplant and perioperative medicine: rapid assessment of graft function and pre-anesthetic liver status.
- Veterinary and preclinical research: liver safety evaluation in animal health and pharmacology studies.
FAQ
What is ALT and why is it measured?
ALT is an intracellular enzyme concentrated in the liver. When liver cells are injured, ALT leaks into the bloodstream, so serum ALT activity is a sensitive early indicator of hepatocellular damage and a key component of liver function panels.
What is the normal reference range for ALT?
Typical adult reference intervals are approximately 7-40 U/L, although exact limits vary with sex, age, body mass index, methodology, and laboratory population. Results should always be interpreted against the reference interval supplied by the performing laboratory.
How long does a rapid ALT test take?
Point-of-care dry-chemistry and cartridge systems report results in roughly 5-15 minutes from application of a fingerstick or venous sample. Central laboratory kinetic assays on automated analyzers typically provide results within 30-60 minutes of sample receipt.
Is fasting required before ALT testing?
Fasting is not strictly required, but an 8-12 hour fast is often recommended to reduce lipemia-related interference, especially when ALT is measured as part of a complete metabolic or lipid panel. Alcohol consumption and strenuous exercise should be avoided for at least 24 hours before sampling.
What causes elevated ALT results?
Common causes include viral hepatitis, nonalcoholic fatty liver disease, alcohol-related liver disease, drug- or herb-induced liver injury, and less commonly autoimmune hepatitis, hemochromatosis, thyroid disease, or muscle injury. Mild transient elevations are frequent and often resolve on repeat testing.
Which sample types are acceptable for rapid ALT testing?
Serum, lithium heparin or EDTA plasma, and whole blood on validated point-of-care systems are all acceptable. Hemolyzed, icteric, or lipemic specimens may produce inaccurate results and should be re-collected or flagged according to the system interference limits.
How does rapid point-of-care ALT testing compare with central laboratory methods?
Well-designed rapid systems demonstrate strong correlation (typically r greater than 0.95) and acceptable bias against IFCC-standardized laboratory assays across the clinical range. Abnormal or unexpected point-of-care results should be confirmed by the central laboratory, particularly when major clinical decisions such as drug discontinuation depend on the value.
Can ALT results be falsely low?
Yes. Prolonged room-temperature storage of unspun clotted blood, repeated freeze-thaw cycles, vitamin B6 deficiency in assays without pyridoxal-5'-phosphate activation, and extreme sample degradation can reduce measured activity. Proper sample handling and adherence to reagent storage and expiration conditions minimize this risk.
